AUTHORS
Karun Neupane, MD, Corbin Wright2, Rida Darji, MD3, Juan Carlos Ramirez, MD4, Jiannong Li5, Ken Harada6, Gabriel De Avila7, David Scheiber-Camoretti8, Brandon Blue, MD9, Julia Fadul10, Ariel Dixon, PharmD11, Syeda Saba Kareem, PharmD12, Blanca Lopez13, Katherine Tobon, PharmD14, Hien Liu, MD15, Ciara Louise L Freeman, MD, PhD16, Frederick L. Locke, MD17, Taiga Nishihori, MD18, Melissa Alsina, MD19, Omar Alexis Castaneda Puglianini, MD20, Kenneth H. Shain, MD, PhD21, Rachid Baz, MD22, Doris K. Hansen, MD23, Ariel F. Grajales-Cruz, MD24
AFFILIATIONS
1 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
2 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
3 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
4 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
5 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
6 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
7 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
8 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
9 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
10 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
11 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
12 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
13 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
14 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
15 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
16 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
17 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
18 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
19 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
20 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
21 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
22 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
23 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
24 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
ABSTRACT
Background
B-cell maturation antigen (BCMA)- and GPRC5D-directed bispecific antibodies (BsAbs) have transformed the management of relapsed/refractory multiple myeloma (RRMM). Comparative real-world data evaluating the effectiveness and safety of these targets remain limited, particularly in heavily pretreated and BCMA-exposed populations.
Methods
We conducted a retrospective study of patients with RRMM treated at Moffitt Cancer Center between August 2022 and September 2025 with BsAbs targeting BCMA (teclistamab or elranatamab) or GPRC5D (talquetamab). Baseline characteristics collected included age, sex, race, ethnicity, ECOG performance status, number of prior lines of therapy, triple/penta refractory disease, high risk cytogenetics (per IMS-IMWG 2025 criteria), plasma cell leukemia, true extra-medullary disease (EMD) and baseline LDH, albumin and beta-2 microglobulin. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), overall response rate (ORR), ≥very good partial response (VGPR) rate, ≥complete response (CR) rate, day-30 and day-90 ORR, MRD by clonoSEQ and safety. To account for baseline differences, inverse probability of treatment weighting (IPTW) using propensity scores was performed, followed by weighted Cox and logistic regression analyses. Prespecified subgroup analyses evaluated treatment interactions according to age, prior BCMA exposure (including belantamab mafodotin, CAR-T and BsAb), true EMD, high risk cytogenetics, penta-refractoriness status, and ECOG performance status. Patients who received BsAb only as a bridging therapy were excluded.
Results
A total of 264 patients were included (94 treated with GPRC5D BsAb and 170 with BCMA BsAbs) with median 6 prior lines, 91% triple-class refractory and 58% penta-refractory disease. Baseline characteristics were similar between two groups. Prior BCMA exposure was more common (83% vs 66%, p=0.01) in the GPRC5D cohort.
In unadjusted survival analyses, ORR was higher with GPRC5D BsAb vs BCMA BsAbs (73% vs 55%, p=0.01), as was the ≥VGPR rate (60% vs 44%, p=0.01), while ≥CR rates were similar (46% vs 38%, p=0.20). Early responses also favored GPRC5D BsAb, with day-30 ORR rates of 66% vs 52% (p=0.03); day-90 ORR rates (86% vs 84%, p=0.70) and best MRD negativity rates (74% vs 72%, p=0.80) were comparable. Median PFS for GPRC5D vs BCMA BsAbs was 9.2 months vs 8.0 months (p=0.48) while median OS was not reached vs 26.2 months (p=0.30). After IPTW adjustment, compared with GPRC5D BsAb, BCMA BsAbs were associated with lower odds of achieving ORR (adjusted OR [aOR] 0.48, 95% CI 0.28–0.82; p=0.01) and ≥VGPR (aOR 0.52, 95% CI 0.31–0.86; p=0.01). However, no significant differences were observed in PFS or OS.
Rates of CRS (41% vs 38%, p=0.60), ICANS (16% vs 12%, p=0.40) and treatment discontinuation due to toxicities (11% vs 9%, p=0.60) were similar with 40% vs 33% patients receiving tocilizumab prophylaxis. Grade 3/4 infections (17% vs 28%, p=0.05) and treatment-related mortality (2.1% vs 8.2%, p=0.05) was lower in GPRC5D cohort. Oral, nail and skin toxicities with talquetamab were seen in 88% patients and neurotoxicity was seen in 4% including at least one patient with cerebellar toxicity. After IPTW adjustment, BCMA BsAbs demonstrated a trend toward higher odds of treatment-related death (aOR 3.66, 95% CI 0.98–23.70; p=0.09) and composite severe toxicities (grade 3/4 infections, ICU admission during cycle 1, treatment discontinuation due to toxicity, and treatment related death) (aOR 1.76, 95% CI 0.99–3.22; p=0.06).
Subgroup analyses showed that compared with talquetamab, BCMA BsAbs resulted in lower odds of response among patients with prior BCMA exposure (interaction OR 0.27, p=0.03) and penta-refractory disease (interaction OR 0.26, p=0.02). No significant treatment interactions were observed for PFS or OS.
Conclusions
GPRC5D BsAb demonstrated higher response rates than BCMA-directed therapy despite greater prior exposure to BCMA-directed therapies though these response advantages did not translate into improved PFS or OS. Safety profiles were generally comparable; however, GPRC5D-directed therapy was associated with lower treatment-related mortality but distinct on-target, off-tumor toxicities.
DISCLOSURES
Karun Neupane, MD: No relevant conflicts of interest to declare.